Effect of Intrathecal Naloxone in the Incidence of Pruritis After C.S

• Status: Completed
• Trial end date: 2021-03-07
• Target enrollment: 0
• Participant gender: Female

Summary

This randomized prospective double-blind trial will be conducted on 80 Full-term pregnant females aged 21- 30 years presented for elective cesarean section under spinal anesthesia where they will be randomly allocated into two equal groups:-

• Group F (40 Patients): Patients in this group will receive spinal anesthesia with 10 mg hyperbaric bupivacaine (2 ml) plus 25 ug of fentanyl (0.5 ml).

• Group FN (40 patients): Patients in this group will receive spinal anesthesia with 10 mg hyperbaric bupivacaine (2 ml) plus 25 ug of fentanyl (0.5 ml) plus 20 ug naloxone.

The study aim is to evaluate the effect of adding an ultra-low dose of naloxone (20 ug) to hyperbaric bupivacaine (10 mg0 and fentanyl (25 ug) in spinal anesthesia for C.S.

Primary outcome: The incidence of pruritis Secondary outcome: The onset, the duration, the site, and the severity of pruritis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Fentanyl; Naloxone

Criteria

Inclusion Criteria:

• Full-term pregnant female aged 21- 30 years presented for elective cesarean section under spinal anesthesia.

Exclusion Criteria:

• Patients with pregnancy less than 36 weeks or more than 40 weeks

• Patients with hypertension, pre-eclampsia, or eclampsia.

• Patients with diabetes

• Patients with cardiovascular disease and /or arrhythmia.

• Patients with placenta previa, accreta, percreta.

• Obese patients with BMI >36 Kg/m2

• Patients with height less than 160 Cm

• Multigravida

• Polyhydramnious patients